A photon-counting spectral detector based on the scanning multislit geometry from Sectra has been developed within the EU-funded Highrex project. It is used in clinical trials to evaluate photon counting tomosynthesis; spectral tomosynthesis; and contrast-enhanced spectral tomosynthesis. A theoretical model of the detector’s spectral performance has been developed and is used to predict the system performance using an ideal observer and a generalized form of the DQE that includes the anatomical noise.

In this presentation, Åslund concluded that standardized DQE measurements show that the spectral detector is highly efficient with low electronic noise, which combined with the efficient scatter rejection makes it suitable for spectral imaging. The model agrees well with experimental data. Contrast-enhanced spectral imaging is feasible in the investigated two-dimensional geometry. This motivates extending model and experiments, e.g. to the tomosynthesis geometry.

Dedicated to decreasing mortality in breast cancer

The HighReX Consortium, which is lead by Sectra and includes 13 clinical and industrial partners from six European countries, is evaluates the potential for contrast-free spectral breast imaging in a new clinical trial. The consortium focuses on development of novel imaging methods based on Sectra´s photon-counting detector technology, which provides the unmatched lowest radiation dose on the market. The objective is to improve early detection and diagnosis of breast cancer and clinical evaluation of the new methods.

On September 1, 2011, Philips acquired the MicroDose operations from Sectra and hence all questions regarding photon-counting, low-dose mammography, MicroDose etc are referred to Philips. For more information on MicroDose Mammography or on the acquisition please go to www.philips.com/microdose

Women's health Dr. Magnus Åslund, HighReX, photon-counting, RSNA 09